Mohammad Azab, M.D., has resigned his position as CEO of Intradigm but will retain his position on Intradigm's board of directors. Dr. Azab will be succeeded by Philip Haworth, Ph.D., who previously served as the company's vice president of business development.
Mark Emkjer has resigned as president and CEO of Accelrys.
Auspex Pharmaceuticals has named Michael Grey as president and CEO and R. Gary Gilmore as chief financial officer.
CEO Mitchell Sayare has left ImmunoGen and has been replaced by Daniel Junius.
Former Molecular Insight Pharmaceuticals CEO David Barlow has resigned from the board, citing differences of opinion.
Ensysce Biosciences has named Dr. Lynn Kirkpatrick as president and CEO.
Gryphon Investors announced that Susan C. Thornton, Ph.D., has been named president and CEO of Synteract Corporation, the holding company that owns Synteract and Vince & Associates Clinical Research.
Promedior has appointed Dominick C. Colangelo as its CEO and a member of the biopharmaceutical company's board of directors.
Impax Laboratories has elected Christopher Mengler as its new president of global pharmaceuticals.
CytRx said Tuesday that Mitchell Fogelman has resigned as chief financial officer and John Caloz has been promoted to the CFO post.
MDS Pharma Services has named Rudy Howard as senior vice-president and chief financial officer.
Kiwa Bio-Tech Products Group Corporation announced that Lianjun Luo, chief financial officer, resigned his position with the company after his employment agreement expired.
Clarus Ventures has promoted Emmett Cunningham, M.D., Ph.D., M.P.H. to partner and Scott Requadt, J.D., M.B.A. to transactional partner.
Nuon Therapeutics announced the appointment of Michael M. Kitt, M.D. to the position of chief medical officer.
Valeant Pharmaceuticals International has appointed Rajiv De Silva as chief operating officer of specialty pharmaceuticals.
Kiadis Pharma named Dr. Maarten Egeler as chief medical officer.
Thadd Vargas has been promoted to senior vice president, business development and Tammy Cameron to vice president, finance at Depomed.
Horizon Therapeutics has named Amy Grahn vice president, clinical operations and Iain Duncan senior vice president of operations.
Xoma has appointed Fred Kurland as vice president, finance and chief financial officer.
ONI BioPharma announced that Dr. Martin Handfield has been appointed to the new position of director, research and development.
Proteonomix has named Steven Byle to its board of directors.